Photodynamic Therapy Then & Now: Current Concepts for Real-W -

Name: Photodynamic Therapy Then & Now: Current Concepts for Real-World Use
Uploaded: 2019-06-26T08:00:00+00:00
Duration: 47 min 3 s
Description: Verteporfin for photodynamic therapy (PDT) has been approved for decades as a treatment for retinal disorders. Eye care professionals need to understand al

Media formats available:

Details

Presenters

Overview
Verteporfin for photodynamic therapy (PDT) has been approved for decades as a treatment for retinal disorders. Eye care professionals need to understand all the real-world clinical scenarios in which the use of PDT alone or in combination with anti-VEGF therapy can be a more efficacious treatment option than anti-VEGF monotherapy. View this engaging webinar to gain insight into PDT treatment options as demonstrated with case examples presented by leading retina specialists. Supported by a grant from Bausch + Lomb.
Learning Objectives
Upon completion of this activity, participants will be better able to:
- Summarize the clinical benefits of photodynamic therapy in patients with retinal disorders.
- Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-vascular endothelial growth factor injections.
- Identify methods for effective photodynamic therapy delivery in clinic settings, including dosing, infusion periods, and determination of treatment size.
- Differentiate the benefits of half fluence PDT and full fluence PDT on a real-world population.
Accreditation
Accreditation Statement Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests: Mark R. Barakat, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegra, Alimera, Genentech, Novartis, and RegenXBio. Shareholder: Ohr, Oxurion. Rishi Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Carl Zeiss Meditec, Genentech, Novartis/Alcon and Regeneron Pharmaceuticals/Bayer. Grant/ Research Support: Apellis. Editorial Support Disclosures, Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/26/2019
Expiration Date: 06/26/2020

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
CME/CE
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
Yewlin E. Chee, MD; Camila Ventura MD, PhD
1.50 credits
- Yewlin E. Chee, MD
- Camila Ventura MD, PhD
- Edward Wood, MD
- Tony Capone Jr, MD
- Katherine E. Talcott, MD
- Nassim Abreu, MD
1.50 credits
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Deepak Sambhara, MD
1.00 credit
- Deepak Sambhara, MD
1.00 credit
To Implant or to Inject?
To Implant or to Inject?
MinuteCE®
To Implant or to Inject?
Katherine E. Talcott, MD; Roger A. Goldberg, MD, MBA
0.75 program credits
- Katherine E. Talcott, MD
- Roger A. Goldberg, MD, MBA
0.75 program credits
Who Needs a TKI? Identifying the Right Candidates
Who Needs a TKI? Identifying the Right Candidates
MinuteCE®
Who Needs a TKI? Identifying the Right Candidates
Roger A. Goldberg, MD, MBA; Christina Y. Weng, MD, MBA, FASRS
0.75 program credits
- Roger A. Goldberg, MD, MBA
- Christina Y. Weng, MD, MBA, FASRS
0.75 program credits

Photodynamic Therapy Then & Now: Current Concepts for Real-World Use

Overview

Learning Objectives

Accreditation

Faculty and Disclosures

System Requirements

Publication Dates

Recommended

Title